CCHR's Legacy: Exposing Psychiatric Abuse and Advancing Global Human Rights
From the first U.S. law in California in 1976 banning electroshock and psychosurgery on children under 12 and banning it for minors under age 14 in Western Australia with criminal penalties if administered, to outlaw DST in Australia with criminal penalties for violators, CCHR's work has helped shape the global mental health landscape—often in the face of intense opposition.
'Many of the reforms we fought for were achieved despite industry resistance to challenging psychiatric coercion and power,' said Jan Eastgate, President of CCHR International. 'That legacy continues today, recognized by survivors, lawmakers, health agencies, and UN experts worldwide.'
In the late 1970s, CCHR helped expose the deaths of 48 patients subjected to Deep Sleep Therapy at Chelmsford Private Hospital in New South Wales, Australia. The practice involved drug-induced comas and repeated electroshock. Most patients were never told they had been shocked, and no informed consent was obtained.
After a 10-year campaign by CCHR and DST survivors, a Royal Commission of Inquiry confirmed the practice was abusive and medically indefensible. In 1983, DST was banned under the NSW Mental Health Act, with criminal penalties imposed for its administration. Justice John Slattery, who led the inquiry, determined that electroshock without consent or by deception is 'an assault.'[1]
He credited CCHR for making the investigation possible, stating the group had 'contributed considerably to advance the cause of the Chelmsford patients.'[2]
An award-winning 60 Minutes Australia program was credited to CCHR for the documents that made its landmark exposé possible.[3] Prominent attorney Patrick Griffin called CCHR's work 'the most sustained and thorough exercise in whistleblowing, investigatory reporting and public interest work in the history of this country—bar none.'
In 1986, a UN Special Rapporteur on Human Rights stated: 'CCHR has been responsible for many great reforms… Laws throughout the world which would otherwise have inhibited even more the rights of patients or would have given psychiatry the power to commit minority groups and individuals against their will, have been defeated by the actions of CCHR.'[4]
Since then, nearly 200 laws have been passed worldwide as a result of CCHR's advocacy. These include:
Independently, in 2024, the California Supreme Court ruled that an ECT device manufacturer must warn doctors of the risks of brain damage and permanent memory loss[7]—a position long advocated by CCHR.
CCHR's investigations into Lake Alice Psychiatric Hospital in New Zealand in the 1970s helped expose the electroshocking of children—many of them Māori—without anesthetic, often to their heads, limbs, or genitals. The abuses included sexual assault, forced drugging, and prolonged isolation.
A 2022 New Zealand Royal Commission cited CCHR's contributions, noting:
'CCHR has remained involved in advocating for survivors…since 1976.' In 2024, the government formally acknowledged the torture of children at Lake Alice. One survivor, Bruce Harkness, called CCHR 'true champions.' CCHR NZ was awarded the 2025 Mitre 10-Kiwibank New Zealand Community of the Year honor. Victor Boyd, who led early inspections of Lake Alice, was appointed a Member of the New Zealand Order of Merit, an award endorsed by King Charles III.
The WHO and UN Office of the High Commissioner for Human Rights issued a joint report in 2023 echoing CCHR's early positions, stating that ECT without consent may constitute torture and should be legislatively banned for children.
In May 2025, a statement by the Vice Chair of the UN Committee on the Rights of Persons with Disabilities, who helped open a CCHR exhibition in Los Angeles, declared: 'Involuntary medication, electroshock, even sterilization—these are inhuman practices… they constitute torture.'
CCHR's co-founder, Dr. Thomas Szasz (1920–2012), was a renowned psychiatrist who called for the abolition of coercive psychiatry. In his own words: 'CCHR…is really the only organization that for the first time in human history has organized a politically, socially, internationally significant voice to combat psychiatry.' When asked how to stop psychiatric abuse, Szasz replied: 'We, ourselves. The pillar…must rest on an informed public.' That principle continues to guide CCHR today.
Eastgate says criticism of those calling for an end to coercive psychiatric practices is self-serving, an attempt to rewrite history to deflect from those who have fought tenaciously for decades to help achieve what is now a growing international condemnation of psychiatric abuses. 'CCHR's work aligns with the world's most respected health and human rights agencies, and it will continue to fight for patients' rights and justice, despite industry resistance.'
CCHR was co-founded by the Church of Scientology and Dr. Szasz and has secured informed consent laws and government inquiries into psychiatric abuse around the world for 56 years.
To learn more, visit: https://www.cchrint.org/2025/07/25/cchrs-legacy-of-reform-exposing-abuse/
Sources:
[1] The Hon. Mr. Acting Justice, J.P. Slattery, A.O., 'Report of the Royal Commission Into Deep Sleep Therapy,' NSW Royal Commission, Vol. 6, Dec. 1990, p. 96
[2] New South Wales Royal Commission into Deep Sleep Therapy, Vol 8, p. 479, Dec.1990
[3] https://www.cchrint.org/2020/12/01/survivors-of-lethal-drug-shock-deep-sleep-therapy-vindicated-after-30-years/
[4] Erica-Irene Daes, Special Rapporteur to the UN Human Rights Commission, Principles, Guidelines and Guarantees for the Protection of Persons Detained on Grounds of Mental Ill-Health or Suffering from Mental Disorder, 1986
[5] Geraden Cann 'Thousands of Australians are receiving ECT without consent every year,' ABC News, 8 June 2025, https://www.abc.net.au/news/2025-06-09/electroconvulsive-therapy-consent-depression/105302318; Australian Capital Territory Mental Health Act 2015,https://classic.austlii.edu.au/au/legis/act/consol_act/mha2015128/s157.html
[6] South Australian Mental Health Act, 2009, ECT section, p. 35
[7] https://www.wisnerbaum.com/blog/2024/june/wisner-baum-prevails-in-landmark-win-for-patient/
MULTIMEDIA:
Image link for media: https://www.Send2Press.com/300dpi/25-0728-s2p-cchrmhealth-300dpi.jpg
Image caption: The Citizens Commission on Human Rights International (CCHR) is reaffirming its legacy of restoring human rights in the mental health field – one that spans more than five decades of exposing psychiatric coercion and abuse, helping drive legal and policy change.
NEWS SOURCE: Citizens Commission on Human Rights
Keywords: Religion and Churches, The Citizens Commission on Human Rights International CCHR, restoring human rights, mental health field, psychiatric coercion and abuse, legal and policy change., LOS ANGELES, Calif.
This press release was issued on behalf of the news source (Citizens Commission on Human Rights) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P128011 APNF0325A
To view the original version, visit: https://www.send2press.com/wire/cchrs-legacy-exposing-psychiatric-abuse-and-advancing-global-human-rights/
© 2025 Send2Press® Newswire, a press release distribution service, Calif., USA.
RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT.
Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
11 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Business Upturn
11 hours ago
- Business Upturn
QuasarMD Unveils Advanced Full-Body Light Therapy Mat to Support Aging Wellness
CHINO, Calif., July 29, 2025 (GLOBE NEWSWIRE) — QuasarMD LLC, a leader in light-based wellness technologies, announces the launch of its Full-Body Light Therapy Mat , a clinically validated, non-invasive solution designed to address the evolving wellness needs of aging adults. The full-body mat features 2,052 high-efficiency LEDs delivering dual-wavelength therapy: 660nm red light for surface-level benefits, and 850nm near-infrared (NIR) for deep penetration. Both wavelengths are clinically proven to provide cellular-level therapeutic effects. Specifically designed for aging users, the system provides gentle yet effective relief for common age-related concerns including joint stiffness, muscle fatigue, circulation challenges, and chronic conditions like arthritis or back and knee pain. Designed with Aging in Mind 'Chronic pain, sleepless nights, and reduced mobility are common challenges as we age,' said a spokesperson for QuasarMD. 'Our full-body light therapy mat was specifically developed to help older adults restore their vitality through scientifically validated, non-invasive technology that integrates effortlessly into daily life.' The QuasarMD Full-Body Light Therapy Mat is FDA-cleared device meeting professional-grade standards. Its home operation couldn't be simpler – just lie down and press a button. Featuring an innovative wrap-around design, the mat cossets the body in comfort to ensure complete light exposure from head to toe. Users can easily customize their therapy experience by adjusting time, intensity, and pulse settings for each session. It has a multi-layered fabric design with an inner layer of TPU that enhances light retention, improving both durability and light efficiency. Additionally, it is waterproof and easy to clean, making it convenient for daily use by seniors and caregivers alike. The QuasarMD mat is more than just a health tool – it's a companion for active aging, offering a drug-free, non-invasive way to manage pain, inflammation, and fatigue. Its gentle warmth and therapeutic light not only ease physical discomfort but also enhance mental well-being, improve blood circulation, promote deep relaxation, and foster an enduring sense of vitality – all essential components of healthy aging. 'Today's aging population is more proactive about wellness than ever,' noted the spokesperson. 'Caregivers, wellness professionals, and older adults increasingly demand safe, science-backed solutions that are both effective and convenient for home use. The evidence supporting red and NIR light therapy is robust – and truly empowering.' 'That's why we've developed this solution: to help people naturally manage discomfort, improve sleep quality, and support long-term vitality – all without medications or invasive treatments.' About the Company QuasarMD LLC is a California-based wellness technology company specializing in FDA-cleared light therapy devices that blend clinical efficacy with user-friendly design. Dedicated to working on well-being through the life stages, it has kept innovating non-invasive devices that assist in recovery, wellness, and vigor through light. The Full-Body Light Therapy Mat is now available for purchase at the official QuasarMD shop and through Amazon . Media Contact:QuasarMD LLC Email: [email protected] Phone: 917-426-2860 Address: 15515 Dupont Avenue, Chino, CA 91710, USA Website: